Aminolevulinate inhibition of human coproporphyrinogen oxidase clarifies coproporphyrin III accumulation in porphyrias
Bioscience Reports · 2026
DOI: 10.1042/bsr20254015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioscience Reports, 2026. Verfasst von Andreas Schedlbauer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance, Parque Tecnológico de Bizkaia, Ed. 800, 48160 Der…. Hauptthemen laut MEDLINE: Coproporphyrinogen Oxidase, Aminolevulinic Acid, Coproporphyrins, Porphyrias. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación.
Abstract (Originalsprache)
Porphyrias are inherited or acquired disorders of heme biosynthesis characterized by heme deficiency and accumulation of toxic intermediates. In δ-aminolevulinic acid dehydratase deficiency porphyria (ALADP), patients consistently present elevated urinary δ-aminolevulinic acid (δ-ALA) and coproporphyrin III (COPRO III), yet the mechanistic basis of COPRO III accumulation remains unclear. This metabolic disturbance is also observed in the porphyria-like associated crises in hereditary tyrosinemia type I (HT1). Here, we investigated the effects of δ-ALA, COPRO III, and lead (Pb2+) on human coproporphyrinogen oxidase (CPOX), a key mitochondrial enzyme in heme biosynthesis. Using purified recombinant CPOX, we show that COPRO III binds with high affinity (KD ≈ 2.1 μM) and acts as a competitive inhibitor, while δ-ALA inhibits CPOX at millimolar concentrations through a non-competitive, likely covalent, mechanism. In vivo, δ-ALA accumulation in an HT1 mouse model led to hepatic COPRO III buildup, consistent with our in vitro findings and supporting a synergistic inhibition model in which δ-ALA promotes secondary COPRO III accumulation that further impairs CPOX. Additionally, Pb2+ was found to inactivate CPOX, likely through oxidative damage, providing a molecular explanation for enzyme dysfunction in porphyrin abnormalities in response to lead intoxication. Together, these results identify multiple metabolite- and toxin-dependent mechanisms that converge on CPOX inhibition, offering new insights into the pathophysiology of ALADP, among other porphyrias, lead intoxication, and HT1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance, Parque Tecnológico de Bizkaia, Ed. 800, 48160 Derio, Spain.
- ATLAS Molecular Pharma, Parque Tecnológico de Bizkaia, Ed. 800, 48160 Derio, Spain.
- CIBERehd, Madrid, Spain.
ORCID-Profile: Oscar Millet
Förderung
- Agencia Estatal de Investigación
Zitieren
APA
Schedlbauer, A., Kratzwald, S., Gómez-Galán, M., Gil-Martínez, J., San Juan, I., Pereira-Ortuzar, T., Lopitz-Otsoa, F., Fernandez-Ramos, D., Mato, J. M., & Millet, O. (2026). Aminolevulinate inhibition of human coproporphyrinogen oxidase clarifies coproporphyrin III accumulation in porphyrias. Bioscience Reports. https://doi.org/10.1042/bsr20254015
Vancouver
Schedlbauer A, Kratzwald S, Gómez-Galán M, Gil-Martínez J, San Juan I, Pereira-Ortuzar T, et al. Aminolevulinate inhibition of human coproporphyrinogen oxidase clarifies coproporphyrin III accumulation in porphyrias. Bioscience Reports. 2026. doi:10.1042/bsr20254015
BibTeX
@article{Schedlbauer2026,
author = {Schedlbauer, Andreas and Kratzwald, Sarah and Gómez-Galán, Margarita and Gil-Martínez, Jon and San Juan, Itxaso and Pereira-Ortuzar, Tania and Lopitz-Otsoa, Fernando and Fernandez-Ramos, David and Mato, José M and Millet, Oscar},
title = {Aminolevulinate inhibition of human coproporphyrinogen oxidase clarifies coproporphyrin III accumulation in porphyrias},
journal = {Bioscience Reports},
year = {2026},
doi = {10.1042/bsr20254015}
}
EUVIMED